<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Molecular markers in acute myeloid leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Molecular markers in acute myeloid leukemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Molecular markers in acute myeloid leukemia</div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup><colgroup span="5" width="18%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Approximate frequency in de-novo AML</td> <td class="subtitle1">Frequency in CN AML</td> <td class="subtitle1">Strong associations</td> <td class="subtitle1">Not recorded with</td> <td class="subtitle1">Outlook</td> </tr> <tr> <td><em><strong>NPM1</strong></em></td> <td>35 percent</td> <td>50 percent</td> <td>CN AML, <em>FLT3</em>-ITD, <em>FLT3</em>-TKD, <em>DNMT3A</em>, <em>IDH1</em>, <em>IDH2</em></td> <td><em>CEBPA</em> double mutant</td> <td>Favorable in patients with CN AML and in elderly patients</td> </tr> <tr> <td><em><strong>CEBPA</strong></em></td> <td>7 percent</td> <td>8 to 19 percent</td> <td>CN AML, <em>FLT3</em>-ITD</td> <td><em>NPM1</em></td> <td>Favorable in patients with CN AML (if biallelic)</td> </tr> <tr> <td><strong><em>FLT3</em>-ITD</strong></td> <td>20 to 25 percent</td> <td>30 to 35 percent</td> <td>CN AML, APL, t(6;9), <em>NPM1</em></td> <td> </td> <td>Adverse in patients with CN AML; could vary with allelic burden; no clear effect in patients with APL</td> </tr> <tr> <td><strong><em>FLT3</em>-TKD</strong></td> <td>5 percent</td> <td>14 percent</td> <td>CN AML, <em>NPM1</em></td> <td> </td> <td>Controversial</td> </tr> <tr> <td><em><strong>KIT</strong></em></td> <td> </td> <td>25 percent</td> <td>Core binding factor leukemias</td> <td>Most other karyotypes</td> <td>Adverse in adult patients with core binding factor leukemias</td> </tr> <tr> <td><strong>TET2</strong></td> <td>8 to 12 percent</td> <td>23 percent</td> <td>Possibly CN AML</td> <td><em>IDH1</em>, <em>IDH2</em></td> <td>Controversial</td> </tr> <tr> <td><em><strong>DNMT3A</strong></em></td> <td>14 to 22 percent</td> <td>20 to 33 percent</td> <td>CN AML, <em>NPM1</em>, <em>FLT3</em></td> <td>Core binding factor leukemias, <em>CEBPA</em>, <em>MLL</em> translocations</td> <td>Possibly adverse in patients with CN AML</td> </tr> <tr> <td><strong><em>IDH1</em>, <em>IDH2</em></strong></td> <td>8 to 16 percent</td> <td>30 percent</td> <td>CN AML, <em>NPM1</em>, <em>FLT3</em></td> <td><em>TET2</em>, <em>WT1</em></td> <td>Controversial</td> </tr> <tr> <td><em><strong>ASXL1</strong></em></td> <td>5 to 30 percent</td> <td>About 10 percent</td> <td>Uncommon with <em>NPM1</em> and <em>FLT3</em></td> <td>Possibly <em>CEBPA</em></td> <td>Adverse in patients with CN AML and older patients; more common in older patients</td> </tr> </tbody></table></div><div class="graphic_lgnd">Changes of miRNAs 15, 16, 155, and 181 among others, have been reported. The prognostic effect varies and studies are needed to assess the individual miRNA families and their interactions with other mutations. Some studies have shown that overexpression of BAALC, MN1, and ERG genes is associated with poorer outcomes, but needs confirmation.</div><div class="graphic_footnotes">AML: acute myeloid leukemia; CN AML: cytogenetically normal acute myeloid leukemia; ITD: internal tandem duplication; TKD: tyrosine kinase domain; APL: acute promyelocytic leukemia.</div><div class="graphic_reference">Reproduced from: Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet 2013; 381:484. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id="graphicVersion">Graphic 88091 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
